Ginkgo ketone ester tablets for the treatment of cognitive impairment associated with chemotherapy for breast cancer - a prospective cohort study.

BACKGROUND

Chemotherapy-related cognitive impairment (CRCI) affects up to 75% of breast cancer patients during treatment, with 35% experiencing persistent post-treatment deficits. Current interventions show limited efficacy, creating urgent need for targeted therapies. Ginkgo Ketone Ester (GBE), containing neuroprotective flavonoids and terpene lactones, represents a potential therapeutic strategy.

METHODS

This 24-week prospective cohort study enrolled 96 breast cancer patients (stage I-III) receiving anthracycline-based chemotherapy. Participants were allocated to GBE intervention (n = 48) or standard care (n = 48) groups. The GBE cohort received tablets containing 14.08-21.12 mg total flavonoids, ≥9.6 mg flavonol glycosides, and ≥2.4 mg terpene lactones (0.25 g, three times daily) for 12 weeks. Cognitive function was assessed using Memory and Executive Screening (MES), Auditory Verbal Learning Test-Huashan Version (AVLT-H), and Shape Trail Test A/B at baseline, week 12, and week 24. Serum biomarkers (glutathione [GSH], reactive oxygen species [ROS], tumor necrosis factor-alpha [TNF-α]) and quality of life measures were evaluated correspondingly.

RESULTS

GBE administration significantly improved cognitive performance compared to controls (P < 0.05). The intervention group demonstrated 23% higher MES scores (72.29 ± 9.09 vs. 64.42 ± 8.63 at week 24), 31% better AVLT-H performance, and maintained stable completion times. Biochemical analysis revealed substantial GSH elevation (56% increase) and ROS reduction (41% decrease) at week 24, while TNF-α remained unchanged. CRCI incidence was significantly lower in the GBE group (66.67% vs. 89.58%, P < 0.007). Treatment compliance reached 89% with no serious adverse events reported.

CONCLUSION

GBE demonstrates significant promise as a neuroprotective intervention for CRCI management, with substantial improvements in cognitive function and oxidative stress biomarkers. The favorable efficacy profile, excellent safety record, and high compliance support GBE's potential as adjunctive CRCI therapy. While neuroinflammatory effects were limited, robust antioxidant restoration and cognitive enhancement warrant further investigation through large-scale randomized controlled trials to validate long-term efficacy and optimize clinical protocols.

CLINICAL TRIAL REGISTRATION

https://www.chictr.org.cn, identifier ChiCTR2200065694.